Atamparib

N/A

Report date: 2026/02/10 20:00:22
NME

Base Information

Drug NameAtamparib
Drug Alias NameRBN-2397ONO-7119
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTCDD-inducible poly [ADP-ribose] polymerase inhibitors
TargetsTCDD-inducible poly [ADP-ribose] polymerase
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited KingdomIsrael +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesRibon Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesNerviano Medical Sciences IncNerviano Medical Sciences (Shanghai) LtdNavino Pharmaceutical Technology (Shanghai) Co Ltd +[7] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A